Monovalent Ebola vaccine (NIAID/Okairos)

N/A

Report date: 2025/12/19 20:01:35

Base Information

Drug NameMonovalent Ebola vaccine (NIAID/Okairos)
Drug Alias NameMonovalent Zaire Ebola Chimpanzee Adenovirus vector vaccine单价埃博拉病毒疫苗 - NIAID/OkairosMonovalent Ebola virus vaccineMonovalent Ebola vaccineEbola candidate vaccine +[10] 
ClassificationVaccines > Application > Prophylactic vaccineVaccines > Vaccine type > Univalent vaccineVaccines > Development/production technology > Recombinant vector vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsHemorrhagic Fever, EbolaVirus Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUgandaSenegal +[9] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNational Institute Of Allergy And Infectious Diseases (Niaid)Reithera Srl
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline PlcUniversity Of OxfordNational Institute Of Allergy And Infectious Diseases (Niaid)
Active IndicationsN/A
Inactive IndicationsHemorrhagic Fever, EbolaVirus Diseases

Other Information

ATC CodeN/A
Related LinksN/A